. 2020 Sep 16;157(1):79–83. doi: 10.1001/jamadermatol.2020.3671

Table 2. Characteristics of Patients With New Cutaneous Melanoma After Starting Immune Checkpoint Inhibitors.

Patient No.	AJCC (8th ed) stage at ICI start (unknown primary)	Primary CMs before ICI start, No.	ICI received before new primary CM diagnosis	ICI start to new primary CM diagnosis, d	Anatomic site (Breslow thickness) of new primary CMs diagnosed after ICI start	ICI received after new primary CM(s) diagnosed	ICI duration, first to last dose, d	Other treatment of metastatic disease		ICI start to last follow-up or death, d	Vital/disease status
Patient No.	AJCC (8th ed) stage at ICI start (unknown primary)	Primary CMs before ICI start, No.	ICI received before new primary CM diagnosis	ICI start to new primary CM diagnosis, d		ICI received after new primary CM(s) diagnosed	ICI duration, first to last dose, d	Before ICI start	After ICI start	ICI start to last follow-up or death, d	Vital/disease status
1	IV (no)	1	Ipi	404	Trunk (in situ)^a^,^b	NA	84	S	NA	2709	Alive, NED
2	IV (no)	2	Pembro	508	Trunk (2.5 mm)^c^,^d	NA	189	R, S	S	977	Alive, NED
3	IV (no)	3	Ipi	391	Trunk (1.1 mm)^a^,^b	Pembro, nivo	2331	R, S	S, C	2331	Alive, NED
4	IV (no)	2	Ipi	162	Trunk (in situ)^a^,^d	Ipi, nivo, pembro	2029	NA	R, S, T, I	2139	Alive, WD
5	IV (no)	3	Ipi	63	H&N (3 mm)^c^,^d	NA	25	R, S	R	2274	Alive, NED
				340	H&N (0.3 mm)
				869	Trunk (in situ)
6	IV (no)	1	Ipi	1347	UE (in situ)^a^,^e	NA	73	S	NA	2853	Alive, NED
7	III (no)	6	Ipi	73	UE (0.4 mm)^c^,^d	NA	31	NA	C	2362	Alive, NED
8	IV (no)	1	Ipi	593	Trunk (in situ)^a^,^b	NA	42	S, C, T	NA	3658	Alive, NED
9	IV (no)	7	Pembro	531	LE (0.3 mm)^a^,^d	NA	341	NA	NA	611	Alive, NED
10	IV (no)	1	Ipi, nivo	492	H&N (in situ)^e^,^f	NA	42	R, S, V	NA	2597	Alive, NED
11	IV (yes)	1	Ipi	240	UE (0.3 mm)^a^,^d	NA	583	S, C	S	3590	Alive, NED
12	IV (yes)	0	Ipi	280	H&N (0.62 mm)^c^,^d	NA	42	NA	R, C, T	492	Dead, DOD
13	IV (no)	1	Ipi, Nivo	365	Trunk (0.45 mm)^a^,^b	Ipi, nivo	966	S, I	R, S, T	1486	Dead, DOD
14	IV (no)	1	Ipi	66	UE (0.3 mm)^c^,^d	Ipi	476	S, V	R, T	519	Dead, DOD
15	IV (no)	1	Ipi	338	LE (invasive)^c^,^d	Ipi	735	S	R, C, T	759	Dead, DOD
16	IV (no)	2	Pembro	765	H&N (in situ)^a^,^b	NA	65	NA	NA	968	Alive, NED
17	IV (no)	2	Ipi	225	LE (in situ)^c^,^d	Ipi	646	C	C, T	680	Dead, DOD
17	IV (no)	2	Ipi	254	H&N (0.3 mm)	Ipi	646	C	C, T	680	Dead, DOD
18	IV (no)	1	Ipi	1435	UE (in situ)^a^,^b	NA	63	S	NA	1727	Dead, DWD
19	IV (no)	1	Pembro	259	UE (0.2 mm)^d^,^f	Ipi	667	R	R, I	989	Alive, WD
20	IV (no)	1	Ipi, nivo, pembro	382	H&N (in situ)^a^,^b	NA	962	R, S	NA	992	Alive, NED
21	IV (yes)	1	Ipi, nivo, pembro	1149	Trunk (0.38 mm)^a^,^d	NA	849	R, S	R	1332	Alive, WD
22	IV (yes)	0	Pembro	592	LE (in situ)^a^,^b	NA	732	NA	NA	1318	Alive, NED
23	IV (yes)	0	Nivo, pembro	488	UE (in situ)^c^,^d	NA	239	NA	NA	693	Alive, NED
23	IV (yes)	0	Nivo, pembro	663	LE (0.46 mm)	NA	239	NA	NA	693	Alive, NED
24	IV (no)	2	Ipi	991	Trunk (in situ)^a^,^d	NA	77	S, V	NA	2414	Alive, NED
25	IV (no)	1	Pembro	159	H&N (in situ)^c^,^d	NA	33	NA	R, S	505	Dead, DWD
26	III (no)	1	Ipi	39	LE (in situ)^a^,^d	NA	42	S, T	NA	199	Dead, DOD
27	IV (no)	5	Ipi, pembro	2409	H&N (in situ)^a^,^d	NA	2277	S, C	NA	3094	Alive, NED
28	IV (no)	3	Ipi, nivo	391	Trunk (0.54 mm)^a^,^b	NA	140	S	NA	1680	Alive, NED
29	III (yes)	2	Ipi, nivo	531	H&N (0.15 mm)^a^,^b	NA	42	NA	NA	2490	Alive, NED
30	IV (yes)	1	Ipi	1477	H&N (in situ)^e^,^f	NA	274	NA	R	2894	Dead, NOS
31	IV (no)	1	Ipi	120	H&N (in situ)^e^,^f	NA	66	R, S	NA	148	Dead, DOD
32	III (no)	1	Ipi	203	LE (0.4 mm)^a^,^b	Pembro	322	NA	S, C	1467	Dead, DOOC
32	III (no)	1	Ipi	254	H&N (in situ)	Pembro	322	NA	S, C	1467	Dead, DOOC
33	IV (no)	2	Ipi, nivo, pembro	693	Trunk (0.5 mm)^a^,^b	Pembro	1232	NA	R, S, C	1308	Dead, DOD
34	IV (no)	6	Ipi, pembro	1740	Trunk (in situ)^a^,^b	NA	1218	R, S, C, T, I	S, T	2769	Alive, NED
34	IV (no)	6	Ipi, pembro	2769	UE (in situ)	NA	1218	R, S, C, T, I	S, T	2769	Alive, NED
35	IV (no)	2	Ipi	2140	H&N (8.4 mm)^e^,^f	Ipi	2588	S	S	2631	Alive, WD
36	III (no)	1	Ipi	844	Trunk (in situ)^a^,^b	NA	62	S, C, I, V, GM-CSF, TNF, IL DNCB	NA	3518	Alive, NED
37	III (no)	1	Ipi	2160	LE (in situ)^c^,^d	NA	522	S	S, C	2862	Alive, NED
38	IV (yes)	0	Ipi	78	Trunk (in situ)^a^,^d	NA	64	S	S	1800	Alive, NED
39	IV (yes)	1	Pembro	118	Trunk (in situ)^a^,^b	NA	727	S	R	902	Alive, NED
40	IV (no)	1	Ipi, pembro	351	Trunk (in situ)^a^,^b	NA	125	NA	R	1703	Alive, WD
41	IV (yes)	0	Ipi	699	UE (0.14 mm)^f^,^e	NA	62	R, S	R	1806	Alive, WD
42	IV (no)	1	Ipi, nivo, pembro	182	Trunk (in situ)^a^,^b	Nivo	336	S	C, T, TVEC	542	Dead, DOD

Abbreviations: AJCC, American Joint Committee on Cancer; C, cytotoxic chemotherapy; CM, cutaneous melanoma; DOD, died of melanoma; DOOC, died of other cause; DWD, died with active disease but of unknown cause; GM-CSF, granulocyte-macrophage colony-stimulating factor; H&N, head and neck; I, other immunotherapy; ICI, immune checkpoint inhibitor; IL DNCB, intralesional dinitrochlorobenzene; ipi, ipilimumab; LE, lower extremity; NA, not applicable; NED, no evidence of disease; nivo, nivolumab; NOS, not otherwise specified; pembro, pembrolizumab; R, radiation; S, surgery; T, VEGFR/PDGFR/multikinase/RAF/BRAF/MEK/PI3K-γ/ERK/CDK targeted therapy; TNF, tumor necrosis factor; TVEC, talimogene laherparepvec; UE, upper extremity; V, vaccine; WD, with disease.

^{^a}

First identified by physician.

^{^b}

Identified during screening examination.

^{^c}

First identified by patient or family.

^{^d}

Identified during other visit type.

^{^e}

Unknown if identified during screening examination or other visit type.

^{^f}

Unknown who first identified lesion.